{"id":17292,"date":"2023-03-30T16:33:00","date_gmt":"2023-03-30T16:33:00","guid":{"rendered":"https:\/\/www.prnasia.com\/story\/archive\/4057601_CN57601_0"},"modified":"2023-03-30T16:33:00","modified_gmt":"2023-03-30T16:33:00","slug":"kintor-pharma-announces-2022-annual-results-and-recent-business-progress","status":"publish","type":"post","link":"https:\/\/transmediavictoria.net.au\/?p=17292","title":{"rendered":"Kintor Pharma Announces 2022 Annual Results and Recent Business Progress"},"content":{"rendered":"<p><span class=\"legendSpanClass\">SUZHOU, <span class=\"xn-location\">China<\/span><\/span>, <span class=\"legendSpanClass\"><span class=\"xn-chron\">March 31, 2023<\/span><\/span> \/PRNewswire\/ &#8212; Kintor Pharmaceutical Limited (Kintor Pharma, HKEX: 9939), a clinical-stage biotechnology company developing innovative small molecules and biological therapeutics, today announced business highlights and financial results for the year ended <span class=\"xn-chron\">31 December 2022<\/span>.<\/p>\n<p><b>Business Highlights<\/b><\/p>\n<ul type=\"disc\">\n<li>Kintor Pharma has made rapid progress on global clinical development, and achieved positive data read-outs of core products during the reporting period.<\/li>\n<li>Kintor Pharma has rolled out the clinical pipeline in dermatology area globally.<\/li>\n<li>Kintor Pharma is actively promoting the business development opportunities in <span class=\"xn-location\">China<\/span> and globally to accelerate the commercialization progress.<\/li>\n<li>Kintor Pharma has raised about <span class=\"xn-money\">$100 million<\/span> through 2 top-up placements during the reporting period.<\/li>\n<li>The company&#8217;s stock has been included in MSCI China Index and Shanghai-Hong Kong Stock Connect, which increased the stock&#8217;s liquidity in the capital market.<\/li>\n<li>The company&#8217;s R&amp;D outcome has been accepted by reputable academic conferences including AACR, ASH and AAD of the U.S., which has demonstrated its R&amp;D capabilities.<\/li>\n<\/ul>\n<p>Dr. <span class=\"xn-person\">Youzhi Tong<\/span>, founder, Chairman, and CEO of Kintor Pharma, commented, 2022 has been a challenging year for the global biotech industry. Under the difficulty market conditions, Kintor Pharma has made rapid progress in R&amp;D, financing and academic publications.&nbsp;<\/p>\n<p>In terms of R&amp;D, the company has made steady progress in its pipeline and achieved positive data read-outs of its core products, including Pyrilutamide (KX-826) for androgenetic alopecia (AGA) indication, GT20029 for AGA and acne vulgaris indications. The Phase II clinical trials of KX-826 for male and female AGA in <span class=\"xn-location\">China<\/span> have reached the primary endpoints, respectively.<\/p>\n<p>Kintor Pharma has rolled out the clinical pipeline in dermatology area globally, and is actively promoting the business development opportunities in <span class=\"xn-location\">China<\/span> and globally to accelerate the commercialization progress. In capital market, the company has raised net proceeds of <span class=\"xn-money\">$100 million<\/span> through two top-up placements during the reporting period. In addition, the company&#8217;s stock has been included in the MSCI China Index and the Shanghai-Hong Kong Stock Connect, further enhanced the stock&#8217;s liquidity in the capital market. In academics, the company&#8217;s research results have been presented at important academic conferences such as AACR, ASH and AAD of the U.S., proving that the company&#8217;s innovation ability and its international influence.<\/p>\n<p>Looking forward, Kintor Pharma will continue to execute the development of the core products in <span class=\"xn-location\">China<\/span> and globally, expecting to accelerate its commercialization process. The company strives to bring safe and effective therapeutics to the patients around the globe, and create value for its shareholders and employees.<\/p>\n<p><b>Rapid Progress on Global Clinical Development and Positive Data Read-outs of Core Products&nbsp;<\/b><\/p>\n<p>As a Biotech company focusing on the R&amp;D and industrialization of potential First-in-Class and Best-in-Class innovative drugs, Kintor Pharma has developed a diversified product pipeline including small-molecule drugs, biologics innovative drugs and combination therapies. At present, the company has seven novel drug candidates with First-in-Class or Best-in-Class potential in Phase I-III clinical stages in <span class=\"xn-location\">China<\/span> and around the world. Since 2022, the company has released positive clinical results of core products, including&nbsp;the Phase II clinical trials of KX-826 for male and female AGA in <span class=\"xn-location\">China<\/span>, respectively, and the Phase I clinical trials of GT20029 for the treatment of AGA and ance in both <span class=\"xn-location\">China<\/span> and the U.S..<\/p>\n<p>Pyrilutamide (KX-826) is a topical androgen receptor (AR) antagonist that is under clinical development for the potential treatment of AGA and acne. KX-826 is the world&#8217;s first AR antagonist for AGA treatment which entered the&nbsp;Phase III clinical trial stage.<\/p>\n<p>On <span class=\"xn-chron\">27 August 2022<\/span>, one of the leading principal investigators of the Phase II clinical trial of KX-826 in <span class=\"xn-location\">China<\/span> for the treatment of male AGA adults, Professor <span class=\"xn-person\">Jianzhong Zhang<\/span> (\u5f20\u5efa\u4e2d) from Peking University People&#8217;s Hospital, released the trial&#8217;s positive results at the 6th Annual Meeting of Chinese Hair Research Society (\u7b2c\u516d\u5c4a\u5168\u56fd\u6bdb\u53d1\u5b66\u672f\u4f1a\u8bae). The results showed that after 24 weeks of treatment, the non-vellus target area hair counts (TAHC) in the 5mg (0.5% concentration) twice daily (BID) KX-826 group increased by 15.34\/cm<sup>2<\/sup>&nbsp;compared with the placebo group from baseline, with a statistical difference (P=0.024).<\/p>\n<p>On <span class=\"xn-chron\">1 December 2022<\/span>, the company announced that the primary endpoint of Phase II clinical trial of KX-826 for female AGA adults in <span class=\"xn-location\">China<\/span> was met. After 24 weeks of treatment, the non-vellus TAHC in the 5mg (0.5% concentration) once daily (QD) KX-826 group increased by 11.39\/cm<sup>2<\/sup>&nbsp;compared with the placebo group from baseline, with a statistical difference (P=0.0087). KX-826 has showed a good safety profile in both trials.<\/p>\n<p>GT20029 is a topical AR-Proteolysis Targeting Chimera (PROTAC) compound that is under clinical development for the potential treatment of AGA and acne. GT20029 is the world&#8217;s first topical PROTAC compound which entered the clinical stage.<\/p>\n<p>On <span class=\"xn-chron\">24 November 2022<\/span>, the company announced the top-line data of the Phase I clinical trial of GT20029 for the treatment of AGA and acne in <span class=\"xn-location\">China<\/span>. The results showed that GT20029 demonstrated good safety, tolerability and pharmacokinetics in healthy subjects.<\/p>\n<p>On <span class=\"xn-chron\">10 February 2023<\/span>, the company announced the top-line data of the Phase I clinical trial of GT20029 for the treatment of AGA and acne in the U.S.. The results showed that GT20029 demonstrated good safety, tolerability and pharmacokinetics following topical single ascending dose (SAD) administration in healthy subjects and multiple ascending dose (MAD) administration in subjects with AGA or acne.<\/p>\n<p>In addition, the company&#8217;s product pipeline includes Pruxelutamide, GT1708F, GT0486, ALK-1 antibody (GT90001) and GT90008 in the clinical stage, and c-Myc inhibitor, compound of other targets out of PROTAC platform and ALK-1\/VEGF bispecific antibody in the preclinical stage.<\/p>\n<p>The company&#8217;s Hedgehog\/SMO inhibitor GT1708F is being explored for both idiopathic pulmonary fibrosis (IPF) indication and combination therapy in blood cancer. The company is now preparing for clinical trial application for the IPF indication.<\/p>\n<p><b>The Growing Visibility in the Capital Market&nbsp;<\/b><\/p>\n<p>Since its listing on the Hong Kong Stock Exchange on <span class=\"xn-chron\">22 May 2020<\/span>, the company&#8217;s development has received long-term support from investors around the world. In 2022, the company successfully completed two top-up placements in the capital market and raised about <span class=\"xn-money\">$100 million<\/span>.<\/p>\n<p>After being included in the Hong Kong Stock Connect program in <span class=\"xn-chron\">September 2021<\/span>, the company&#8217;s stock has been included in the Shanghai-Hong Kong Stock Connect in <span class=\"xn-chron\">March 2023<\/span>, further expanding the company&#8217;s mainland investor pool, improving its liquidity and the market influence. Thus benefits the company&#8217;s future development prospects. In addition, Kintor Pharma&#8217;s stock have been included in the MSCI China Index during the reporting period.<\/p>\n<p><b>Increasing Presence in Reputable Academic Seminars and Conferences<\/b><\/p>\n<p>Since 2022, Kintor Pharma&#8217;s R&amp;D outcome&nbsp;has been accepted&nbsp;by reputable&nbsp;academic conferences and journals, proving&nbsp;that the company&#8217;s innovation ability and its international influence, and further demonstrating the First-in-Class and Best-in-Class potential of the company&#8217;s product pipeline.<\/p>\n<ul type=\"square\">\n<li>Kintor Pharma&#8217;s KX-826 and GT20029 for treatment of AGA&nbsp;and acne presented at AAD 2023<\/li>\n<li>Kintor Pharma&#8217;s Hedgehog\/SMO inhibitor GT1708F for the treatment of Acute Myeloid Leukemia (AML) presented at AACR 2023<\/li>\n<li>Oral Presentation highlighting the data from novel dual c-Myc\/GSPT1 degrader GT19715 at ASH 2022<\/li>\n<li>Pruxelutamide for treatment of COVID-19 and a c-Myc degrader for treatment of blood cancer and small cell lung cancers (SCLC) presented at AACR 2022<\/li>\n<li>The study result of GT19715, a novel dual-target degrader of C-Myc\/GSPT1, was published in the journal Clinical Lymphoma, Myeloma &amp; Leukemia<\/li>\n<li>The study result of the Phase Ib clinical trial of Pruxelutamide for treatment of breast Cancer was published in the European Journal of Cancer (EJC)<\/li>\n<\/ul>\n<p><b>Industry and Capital Market Awards&nbsp;<\/b><\/p>\n<p>Kintor Pharma&#8217;s persistent efforts in R&amp;D has been widely recognized in the industry and has won many industry and capital market awards.<\/p>\n<ul type=\"square\">\n<li>Top 15 Biotech of the Top 100 Hong Kong Listed Companies<\/li>\n<li>Top 10 Innovative Pharmaceutical Companies in 2022<\/li>\n<li>R&amp;D Innovation Outstanding Contribution Award in 2021<\/li>\n<li>Top 20 Biomedical Innovation Potential List in 2022<\/li>\n<li>TOP 30 Innovative Small Molecule Pharmaceutical&nbsp;Companies&nbsp;in <span class=\"xn-location\">China<\/span> in 2021<\/li>\n<li>&nbsp;TOP 20 Most Influential Small Molecule&nbsp;Pharmaceutical&nbsp;Innovation&nbsp;Companies&nbsp;in 2022<\/li>\n<li>Jishi Cup&nbsp;Top 10 Pharmaceutical Innovation Companies in&nbsp;2021<\/li>\n<li>Most Valuable Pharmaceutical and Medical Companies<\/li>\n<\/ul>\n<p><b>Other Business Updates&nbsp;<\/b><\/p>\n<p>In <span class=\"xn-chron\">August 2022<\/span>, Dr. <span class=\"xn-person\">Lu Qun<\/span>, our Chief Technology Officer, was elected as a &#8220;2022 Gusu Innovation and Entrepreneurship Leading Talent&#8221;.<\/p>\n<p>In <span class=\"xn-chron\">May 2022<\/span>, the company has received the approval to set up a Doctors workstation in <span class=\"xn-location\">Guangdong Province<\/span> by the Human Resources and Social Security&nbsp;Department&nbsp;of <span class=\"xn-location\">Guangdong Province<\/span>.<\/p>\n<p><b>Financial Highlights<\/b><\/p>\n<p>As of <span class=\"xn-chron\">31 December 2022<\/span>, the company&#8217;s research and development costs increased by <span class=\"xn-money\">RMB828 million<\/span>, up by 7.8%, from <span class=\"xn-money\">RMB767.9 million<\/span> for the year ended <span class=\"xn-chron\">31 December 2021<\/span>. The increased R&amp;D costs were mainly attributable to the ongoing Phase III clinical trials, including those of Pruxelutamide for the indication of COVID-19 and mCRPC, and KX-826 for the indication of AGA during the reporting period.<\/p>\n<p>The company had cash and cash equivalents and time deposits of <span class=\"xn-money\">RMB875.3 million<\/span> as at <span class=\"xn-chron\">31 December 2022<\/span>, including utilised bank facilities of <span class=\"xn-money\">RMB 276.5 million<\/span>. In addition, the company also had unutilised bank facilities of <span class=\"xn-money\">RMB 120.0 million<\/span> as at <span class=\"xn-chron\">31 December 2022<\/span>. The company has sufficient cash on hand to support the advancement of the clinical trials and R&amp;D.<\/p>\n<p>*For more details, please refer to the 2022 annual results announcement.<\/p>\n<p>About Kintor Pharmaceutical Limited<\/p>\n<p>Kintor Pharmaceutical Limited is developing and commercializing a robust pipeline of innovative small molecule and biological therapeutics for androgen-receptor-related disease areas with unmet medical needs, including COVID-19, prostate, breast and liver cancers, alopecia and acne. For more information, visit <a href=\"http:\/\/www.kintor.com.cn\" rel=\"nofollow\">www.kintor.com.cn<\/a>.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>SUZHOU, China, March 31, 2023 \/PRNewswire\/ &#8212; Kintor Pharmaceutical Limited (Kintor Pharma, HKEX: 9939), a clinical-stage biotechnology company developing innovative small molecules and biological therapeutics, today announced business highlights and financial results for the year ended 31 December 2022. Business Highlights Kintor Pharma has made rapid progress on global clinical development, and achieved positive data [&hellip;]<\/p>\n","protected":false},"author":8,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[20],"tags":[],"class_list":["post-17292","post","type-post","status-publish","format-standard","hentry","category-business-news"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.9 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Kintor Pharma Announces 2022 Annual Results and Recent Business Progress - My Blog<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/transmediavictoria.net.au\/?p=17292\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Kintor Pharma Announces 2022 Annual Results and Recent Business Progress - My Blog\" \/>\n<meta property=\"og:description\" content=\"SUZHOU, China, March 31, 2023 \/PRNewswire\/ &#8212; Kintor Pharmaceutical Limited (Kintor Pharma, HKEX: 9939), a clinical-stage biotechnology company developing innovative small molecules and biological therapeutics, today announced business highlights and financial results for the year ended 31 December 2022. Business Highlights Kintor Pharma has made rapid progress on global clinical development, and achieved positive data [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/transmediavictoria.net.au\/?p=17292\" \/>\n<meta property=\"og:site_name\" content=\"My Blog\" \/>\n<meta property=\"article:published_time\" content=\"2023-03-30T16:33:00+00:00\" \/>\n<meta name=\"author\" content=\"admin_tony\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"admin_tony\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"8 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/transmediavictoria.net.au\\\/?p=17292#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/transmediavictoria.net.au\\\/?p=17292\"},\"author\":{\"name\":\"admin_tony\",\"@id\":\"https:\\\/\\\/transmediavictoria.net.au\\\/#\\\/schema\\\/person\\\/5b51d407d652c0aa802bea269ea5d7e7\"},\"headline\":\"Kintor Pharma Announces 2022 Annual Results and Recent Business Progress\",\"datePublished\":\"2023-03-30T16:33:00+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/transmediavictoria.net.au\\\/?p=17292\"},\"wordCount\":1557,\"articleSection\":[\"Business News\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/transmediavictoria.net.au\\\/?p=17292\",\"url\":\"https:\\\/\\\/transmediavictoria.net.au\\\/?p=17292\",\"name\":\"Kintor Pharma Announces 2022 Annual Results and Recent Business Progress - My Blog\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/transmediavictoria.net.au\\\/#website\"},\"datePublished\":\"2023-03-30T16:33:00+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/transmediavictoria.net.au\\\/#\\\/schema\\\/person\\\/5b51d407d652c0aa802bea269ea5d7e7\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/transmediavictoria.net.au\\\/?p=17292#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/transmediavictoria.net.au\\\/?p=17292\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/transmediavictoria.net.au\\\/?p=17292#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/transmediavictoria.net.au\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Kintor Pharma Announces 2022 Annual Results and Recent Business Progress\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/transmediavictoria.net.au\\\/#website\",\"url\":\"https:\\\/\\\/transmediavictoria.net.au\\\/\",\"name\":\"My Blog\",\"description\":\"My WordPress Blog\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/transmediavictoria.net.au\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/transmediavictoria.net.au\\\/#\\\/schema\\\/person\\\/5b51d407d652c0aa802bea269ea5d7e7\",\"name\":\"admin_tony\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/102836fe5f9cd6c64e96e90e7341dbc815b7d12726a85708326dc0db40afd906?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/102836fe5f9cd6c64e96e90e7341dbc815b7d12726a85708326dc0db40afd906?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/102836fe5f9cd6c64e96e90e7341dbc815b7d12726a85708326dc0db40afd906?s=96&d=mm&r=g\",\"caption\":\"admin_tony\"},\"url\":\"https:\\\/\\\/transmediavictoria.net.au\\\/?author=8\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Kintor Pharma Announces 2022 Annual Results and Recent Business Progress - My Blog","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/transmediavictoria.net.au\/?p=17292","og_locale":"en_US","og_type":"article","og_title":"Kintor Pharma Announces 2022 Annual Results and Recent Business Progress - My Blog","og_description":"SUZHOU, China, March 31, 2023 \/PRNewswire\/ &#8212; Kintor Pharmaceutical Limited (Kintor Pharma, HKEX: 9939), a clinical-stage biotechnology company developing innovative small molecules and biological therapeutics, today announced business highlights and financial results for the year ended 31 December 2022. Business Highlights Kintor Pharma has made rapid progress on global clinical development, and achieved positive data [&hellip;]","og_url":"https:\/\/transmediavictoria.net.au\/?p=17292","og_site_name":"My Blog","article_published_time":"2023-03-30T16:33:00+00:00","author":"admin_tony","twitter_card":"summary_large_image","twitter_misc":{"Written by":"admin_tony","Est. reading time":"8 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/transmediavictoria.net.au\/?p=17292#article","isPartOf":{"@id":"https:\/\/transmediavictoria.net.au\/?p=17292"},"author":{"name":"admin_tony","@id":"https:\/\/transmediavictoria.net.au\/#\/schema\/person\/5b51d407d652c0aa802bea269ea5d7e7"},"headline":"Kintor Pharma Announces 2022 Annual Results and Recent Business Progress","datePublished":"2023-03-30T16:33:00+00:00","mainEntityOfPage":{"@id":"https:\/\/transmediavictoria.net.au\/?p=17292"},"wordCount":1557,"articleSection":["Business News"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/transmediavictoria.net.au\/?p=17292","url":"https:\/\/transmediavictoria.net.au\/?p=17292","name":"Kintor Pharma Announces 2022 Annual Results and Recent Business Progress - My Blog","isPartOf":{"@id":"https:\/\/transmediavictoria.net.au\/#website"},"datePublished":"2023-03-30T16:33:00+00:00","author":{"@id":"https:\/\/transmediavictoria.net.au\/#\/schema\/person\/5b51d407d652c0aa802bea269ea5d7e7"},"breadcrumb":{"@id":"https:\/\/transmediavictoria.net.au\/?p=17292#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/transmediavictoria.net.au\/?p=17292"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/transmediavictoria.net.au\/?p=17292#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/transmediavictoria.net.au\/"},{"@type":"ListItem","position":2,"name":"Kintor Pharma Announces 2022 Annual Results and Recent Business Progress"}]},{"@type":"WebSite","@id":"https:\/\/transmediavictoria.net.au\/#website","url":"https:\/\/transmediavictoria.net.au\/","name":"My Blog","description":"My WordPress Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/transmediavictoria.net.au\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/transmediavictoria.net.au\/#\/schema\/person\/5b51d407d652c0aa802bea269ea5d7e7","name":"admin_tony","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/102836fe5f9cd6c64e96e90e7341dbc815b7d12726a85708326dc0db40afd906?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/102836fe5f9cd6c64e96e90e7341dbc815b7d12726a85708326dc0db40afd906?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/102836fe5f9cd6c64e96e90e7341dbc815b7d12726a85708326dc0db40afd906?s=96&d=mm&r=g","caption":"admin_tony"},"url":"https:\/\/transmediavictoria.net.au\/?author=8"}]}},"_links":{"self":[{"href":"https:\/\/transmediavictoria.net.au\/index.php?rest_route=\/wp\/v2\/posts\/17292","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/transmediavictoria.net.au\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/transmediavictoria.net.au\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/transmediavictoria.net.au\/index.php?rest_route=\/wp\/v2\/users\/8"}],"replies":[{"embeddable":true,"href":"https:\/\/transmediavictoria.net.au\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=17292"}],"version-history":[{"count":0,"href":"https:\/\/transmediavictoria.net.au\/index.php?rest_route=\/wp\/v2\/posts\/17292\/revisions"}],"wp:attachment":[{"href":"https:\/\/transmediavictoria.net.au\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=17292"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/transmediavictoria.net.au\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=17292"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/transmediavictoria.net.au\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=17292"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}